Errors-in-variables in joint population pharmacokinetic/pharmacodynamic modeling

被引:17
作者
Bennett, J
Wakefield, J
机构
[1] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, London, England
[2] Univ Washington, Dept Stat, Seattle, WA 98195 USA
[3] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
关键词
errors-in-variables; feedback; hierarchical models; measurement error; predictive distributions; prior information;
D O I
10.1111/j.0006-341X.2001.00803.x
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Pharmacokinetic (PK) models describe the relationship between the administered dose and the concentration of drug (and/or metabolite) in the blood as a function of time. Pharmacodynamic (PD) models describe the relationship between the concentration in the blood (or the dose) and the biologic response. Population PK/PD studies aim to determine the sources of variability in the observed concentrations/responses across groups of individuals. In this article, we consider the joint modeling of PK/PD data. The natural approach is to specify a joint model in which the concentration and response data are simultaneously modeled. Unfortunately, this approach may not Lie optimal if, due to sparsity of concentration data, all overly simple PK model is specified. As all alternative, we propose all errors-in-variables approach in which the observed-concentration data are assumed to be measured with error without reference to a specific PK model. We give all example of all analysis of PK/PD data obtained following administration of all anticoagulant drug. The study was originally carried out in order to make dosage recommendations. The prior for the distribution of the true concentrations, which may incorporate all individual's covariate information, is derived as a predictive distribution from all earlier study. The errors-in-variables approach is compared with the joint modeling approach and more naive methods in which the observed concentrations, or the separately modeled concentrations, are substituted into the response model. Throughout, a Bayesian approach is taken with implementation via Markov chain Monte Carlo methods.
引用
收藏
页码:803 / 812
页数:10
相关论文
共 28 条
[1]   A POPULATION ANALYSIS OF THE PHARMACOKINETICS AND PHARMACODYNAMICS OF MIDAZOLAM IN THE RAT [J].
AARONS, L ;
MANDEMA, JW ;
DANHOF, M .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1991, 19 (05) :485-496
[2]  
[Anonymous], DRUGS PHARM SCI
[3]  
[Anonymous], 1996, MARKOV CHAIN MONTE C
[4]   Methodological issues in pharmacokinetic-pharmacodynamic modelling [J].
Bellissant, E ;
Sébille, V ;
Paintaud, G .
CLINICAL PHARMACOKINETICS, 1998, 35 (02) :151-166
[5]   Comparison of a direct and indirect population pharmacodynamic model: Application to recombinant human erythropoietin in athletes [J].
Bressolle, F ;
Audran, M ;
Gareau, R ;
Pham, TN ;
Gomeni, R .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1997, 25 (03) :263-275
[6]  
Carroll RJ., 1995, MEASUREMENT ERROR NO
[7]  
Davidian M., 1995, NONLINEAR MODELS REP
[8]   Prevention of thromboembolism with use of recombinant hirudin - Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement [J].
Eriksson, BI ;
Ekman, S ;
Lindbratt, S ;
Baur, M ;
Bach, D ;
Torholm, C ;
Kalebo, P ;
Close, P .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1997, 79A (03) :326-333
[9]   A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement [J].
Eriksson, BI ;
WilleJorgensen, P ;
Kalebo, P ;
Mouret, P ;
Rosencher, N ;
Bosch, P ;
Baur, M ;
Ekman, S ;
Bach, D ;
Lindbratt, S ;
Close, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (19) :1329-1335
[10]  
Fuller W. A., 2009, Measurement error models